NASDAQ:KLDO Kaleido Biosciences - KLDO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kaleido Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.0002 0.00 (0.00%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.00▼$0.14Volume1,950 shsAverage Volume13,721 shsMarket Capitalization$8,524.60P/E RatioN/ADividend YieldN/APrice Target$1.70 ProfileAnalyst RatingsChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Kaleido Biosciences MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside849,900.0% Upside$1.70 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.27) to ($1.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.64 out of 5 stars 3.0 Analyst's Opinion Consensus RatingKaleido Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.70, Kaleido Biosciences has a forecasted upside of 849,900.0% from its current price of $0.00.Amount of Analyst CoverageKaleido Biosciences has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for KLDO. Previous Next 0.0 Dividend Strength Dividend YieldKaleido Biosciences does not currently pay a dividend.Dividend GrowthKaleido Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KLDO. Previous Next 1.2 News and Social Media Coverage News SentimentKaleido Biosciences has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kaleido Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Kaleido Biosciences is held by insiders.Percentage Held by Institutions81.56% of the stock of Kaleido Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kaleido Biosciences are expected to grow in the coming year, from ($2.27) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kaleido Biosciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kaleido Biosciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Kaleido Biosciences (NASDAQ:KLDO) StockKaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. It focuses on leveraging the microbiome organ to treat disease and improve human health. The firm offers microbiome metabolic therapies (MMT), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of the organ's existing microbes. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan on January 27, 2015 and is headquartered in Lexington, MA.Read More Receive KLDO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address KLDO Stock News HeadlinesDecember 17, 2022 | seekingalpha.comKLDO Kaleido Biosciences, Inc.November 10, 2022 | technews.tmcnet.comVoLTE Roaming Readiness Ranked As High Priority For Mobile Operators: Kaleido Q3 2022 Mno SurveyMarch 26, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastSeptember 27, 2022 | tmcnet.comSyniverse Earns Industry Honors in Roaming and Data & Financial Clearing from Kaleido IntelligenceSeptember 12, 2022 | benzinga.comAirlinq, Tata Communications and Giesecke+Devrient, Recognised as Champion Cellular IoT Connectivity Vendors by Kaleido IntelligenceSeptember 5, 2022 | benzinga.comExclusive Free Roaming Insights Available as Kaleido Becomes GSMA MemberJuly 26, 2022 | apnews.comBCE To Provide $5 Billion Operator Revenue Opportunity From Permanently Roaming IoT Devices Over the Next 5 Years: Kaleido IntelligenceJuly 21, 2022 | msn.comEthereum’s Kaleido Collaborates With Polygon for Web3 AdoptionMarch 26, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastJune 14, 2022 | morningstar.comKaleido Biosciences Inc - Stock Price vs Fair Value KLDOJune 7, 2022 | tmcnet.comSecurity and Design are the biggest knots to untangle, according to the largest-ever IoT connectivity survey run by Kaleido IntelligenceMay 16, 2022 | uk.finance.yahoo.comKaleido Biosciences, Inc. (KLDO)April 15, 2022 | seekingalpha.comATER, HNRG and AGLE among mid-day moversApril 8, 2022 | benzinga.comKaleido Biosciences Shares Halted On Code News PendingApril 8, 2022 | finance.yahoo.comKaleido Biosciences Shares Plunging To 52-Week Low, Read WhyApril 8, 2022 | msn.comFlagship’s Kaleido Biosciences shuts down, as more biotechs lay off staffApril 8, 2022 | seekingalpha.comKaleido Biosciences to delist from Nasdaq as business operations endApril 8, 2022 | bizjournals.comKaleido Biosciences shuts downApril 1, 2022 | finance.yahoo.comNovartis (NVS) Beovu Gets Label Expansion for DME in EUMarch 31, 2022 | finance.yahoo.comDare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue EstimatesMarch 25, 2022 | finance.yahoo.comBristol Myers (BMY) Gains 16% YTD: Will the Momentum Continue?March 24, 2022 | finance.yahoo.comRezolute (RZLT) Posts Positive Data From Congenital HI StudyMarch 16, 2022 | finance.yahoo.comRadius Health Announces Leadership AppointmentsMarch 15, 2022 | finance.yahoo.comAnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet GoalMarch 1, 2022 | finance.yahoo.comAcadia (ACAD) Q4 Earnings & Revenues Fall Shy of EstimatesFebruary 24, 2022 | finance.yahoo.comGlobal Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/YFebruary 24, 2022 | finance.yahoo.comKaleido Biosciences, Inc. (KLDO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KLDO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address KLDO Company Calendar Last Earnings11/01/2021Today3/26/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KLDO CUSIPN/A CIK1751299 Webwww.kaleido.com Phone(617) 674-9000FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Stock Price Forecast$1.70 High Stock Price Forecast$1.70 Low Stock Price Forecast$1.70 Forecasted Upside/Downside+849,900.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.10 million Price / Sales0.01 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares42,623,000Free Float38,787,000Market Cap$8,524.60 OptionableNot Optionable Beta-0.06 Key ExecutivesKimberly HocknellSenior Vice President-Technical OperationsKey CompetitorsGenocea BiosciencesNASDAQ:GNCAAllied Healthcare ProductsNASDAQ:AHPIAinosNASDAQ:AIMDWAlopexxNASDAQ:ALPXAlpha Tau MedicalNASDAQ:DRTSWView All Competitors KLDO Stock - Frequently Asked Questions Should I buy or sell Kaleido Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KLDO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KLDO, but not buy additional shares or sell existing shares. View KLDO analyst ratings or view top-rated stocks. What is Kaleido Biosciences' stock price forecast for 2023? 1 equities research analysts have issued 1-year price targets for Kaleido Biosciences' shares. Their KLDO share price forecasts range from $1.70 to $1.70. On average, they anticipate the company's share price to reach $1.70 in the next year. This suggests a possible upside of 849,900.0% from the stock's current price. View analysts price targets for KLDO or view top-rated stocks among Wall Street analysts. How have KLDO shares performed in 2023? Kaleido Biosciences' stock was trading at $0.0005 at the beginning of 2023. Since then, KLDO stock has decreased by 60.0% and is now trading at $0.0002. View the best growth stocks for 2023 here. When is Kaleido Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our KLDO earnings forecast. How were Kaleido Biosciences' earnings last quarter? Kaleido Biosciences, Inc. (NASDAQ:KLDO) released its quarterly earnings results on Monday, November, 1st. The company reported ($0.54) EPS for the quarter, meeting analysts' consensus estimates of ($0.54). The business earned $0.10 million during the quarter, compared to the consensus estimate of $0.25 million. What other stocks do shareholders of Kaleido Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK). When did Kaleido Biosciences IPO? (KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Kaleido Biosciences' stock symbol? Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO." How do I buy shares of Kaleido Biosciences? Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kaleido Biosciences' stock price today? One share of KLDO stock can currently be purchased for approximately $0.00. How much money does Kaleido Biosciences make? Kaleido Biosciences (NASDAQ:KLDO) has a market capitalization of $8,524.60 and generates $1.10 million in revenue each year. How can I contact Kaleido Biosciences? The official website for the company is www.kaleido.com. The company can be reached via phone at (617) 674-9000. This page (NASDAQ:KLDO) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.